Bridging chemotherapy, which is at times given for disease control during the CAR-T manufacturing period, was identified as a risk factor for severe infection before day 30 amongst 85 adults receiving CD19-targeted CAR T-cell therapy for DLBCL (16). Here, CD19 is linked to diffuse large B-cell lymphoma.